Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 3
2019 2
2020 4
2022 2
2023 1
2024 3
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study.
Dennis JM, Young KG, Cardoso P, Güdemann LM, McGovern AP, Farmer A, Holman RR, Sattar N, McKinley TJ, Pearson ER, Jones AG, Shields BM, Hattersley AT; MASTERMIND Consortium. Dennis JM, et al. Lancet. 2025 Mar 1;405(10480):701-714. doi: 10.1016/S0140-6736(24)02617-5. Epub 2025 Feb 25. Lancet. 2025. PMID: 40020703 Free article.
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
Cardoso P, Young KG, Nair ATN, Hopkins R, McGovern AP, Haider E, Karunaratne P, Donnelly L, Mateen BA, Sattar N, Holman RR, Bowden J, Hattersley AT, Pearson ER, Jones AG, Shields BM, McKinley TJ, Dennis JM; MASTERMIND consortium. Cardoso P, et al. Diabetologia. 2024 May;67(5):822-836. doi: 10.1007/s00125-024-06099-3. Epub 2024 Feb 22. Diabetologia. 2024. PMID: 38388753 Free PMC article.
Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach.
Güdemann LM, Young KG, Thomas NJM, Hopkins R, Challen R, Jones AG, Hattersley AT, Pearson ER, Shields BM, Bowden J, Dennis JM, McGovern AP; MASTERMIND consortium. Güdemann LM, et al. Diabetologia. 2024 Sep;67(9):1817-1827. doi: 10.1007/s00125-024-06190-9. Epub 2024 Jun 5. Diabetologia. 2024. PMID: 38836934 Free PMC article.
Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study.
Dennis JM, Young KG, McGovern AP, Mateen BA, Vollmer SJ, Simpson MD, Henley WE, Holman RR, Sattar N, Pearson ER, Hattersley AT, Jones AG, Shields BM; MASTERMIND consortium. Dennis JM, et al. Lancet Digit Health. 2022 Dec;4(12):e873-e883. doi: 10.1016/S2589-7500(22)00174-1. Lancet Digit Health. 2022. PMID: 36427949 Free article.
20 results